Sarah Kavanagh - Bausch Health Independent Director
| BHC Stock | USD 8.71 0.09 1.04% |
Director
Ms. Sarah B. Kavanagh is an Independent Director of the Company. She has served on the Board since July 2016. From June 2011 through May 2016, she served as a Commissioner of the Ontario Securities Commission, where she also served as chairperson of the audit committee starting in 2014. Between 1999 and 2010, Ms. Kavanagh served in various senior investment banking roles at Scotia Capital Inc., including ViceChair and CoHead of Diversified Industries Group, Head of Equity Capital Markets, Head of Investment Banking. Prior to Scotia Capital, she held several senior financial positions with operating companies. She started her career as an investment banker with a bulge bracket firm in New York. Ms. Kavanagh graduated from Harvard Business School with a Masters of Business Administration and received a Bachelor of Arts degree in Economics from Williams College since 2016.
| Age | 63 |
| Tenure | 8 years |
| Address | 2150 St. ElzEar Boulevard West, Laval, QC, Canada, H7L 4A8 |
| Phone | 514 744 6792 |
| Web | https://www.bauschhealth.com |
Bausch Health Management Efficiency
The company has Return on Asset of 0.0382 % which means that on every $100 spent on assets, it made $0.0382 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (6.8652) %, meaning that it generated no profit with money invested by stockholders. Bausch Health's management efficiency ratios could be used to measure how well Bausch Health manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.61, whereas Return On Tangible Assets are projected to grow to (0.06). At present, Bausch Health's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 2.7 B, whereas Total Assets are forecasted to decline to about 14.9 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jim Umpleby | Chevron Corp | 59 | |
| Tyler Jacks | Amgen Inc | 57 | |
| Marillyn Hewson | Chevron Corp | 67 | |
| Wanda Austin | Amgen Inc | 63 | |
| Aida Alvarez | HP Inc | 71 | |
| Timothy | Walmart | 58 | |
| Robert Denham | Chevron Corp | 71 | |
| Enrique Hernandez | Chevron Corp | 64 | |
| Greg Garland | Amgen Inc | 56 | |
| Pamela Craig | Walmart | 60 | |
| Ian Saines | Air Lease | 58 | |
| Stephen Easterbrook | Walmart | 50 | |
| Ronald Sugar | Amgen Inc | 69 | |
| Francois Carbonnel | Amgen Inc | 69 | |
| Matthew Hart | Air Lease | 69 | |
| Inge Thulin | Chevron Corp | 64 | |
| Cesar Conde | Walmart | 47 | |
| Robert Bennett | HP Inc | 62 | |
| Sarah Friar | Walmart | 47 | |
| Thomas Horton | Walmart | 59 | |
| James Skinner | HP Inc | 70 | |
Management Performance
| Return On Equity | -6.87 | ||||
| Return On Asset | 0.0382 |
Bausch Health Companies Leadership Team
Elected by the shareholders, the Bausch Health's board of directors comprises two types of representatives: Bausch Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bausch. The board's role is to monitor Bausch Health's management team and ensure that shareholders' interests are well served. Bausch Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bausch Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| D Hale, Independent Director | ||
| Jeff Hartness, Commercial Access | ||
| John Barresi, Controller, VP | ||
| Sarah Kavanagh, Independent Director | ||
| Arthur Shannon, IR Contact Officer | ||
| Tage MD, Chief RD | ||
| William Humphries, Executive Vice President Company Group Chairman, Dermatology | ||
| Robert Butz, VP Affairs | ||
| Richard DeSchutter, Independent Director | ||
| Robert Hale, Independent Director | ||
| Paul Herendeen, Chief Financial Officer, Executive Vice President | ||
| Brett Icahn, Independent Director | ||
| Richard Schutter, Independent Director | ||
| Seana Carson, Executive Counsel | ||
| Josh Coyle, Senior Salix | ||
| Amy Wechsler, Independent Director | ||
| Graham Jackson, Senior Officer | ||
| Sam Will, Senior Vice President - Finance, Chief Accounting Officer, Controller | ||
| Robert Power, Independent Director | ||
| Thomas Vadaketh, Ex CFO | ||
| Argeris Karabelas, Independent Director | ||
| Kathleen Fitzpatrick, Senior Officer | ||
| Joseph Gordon, President and Co-Head Bausch + Lomb/International | ||
| Jiny MBA, Senior Medical | ||
| Christina Ackermann, Executive Vice President, General Counsel and Head of Commercial Operations | ||
| Thomas Ross, Lead Independent Director | ||
| Donald Pearl, Senior Dermatologics | ||
| Andrew Eschenbach, Independent Director | ||
| Mirza Dautbegovic, Senior COO | ||
| Joseph Papa, Chairman of the Board, Chief Executive Officer | ||
| Mark McKenna, President - Salix Pharmaceuticals | ||
| Elif McDonald, Director, Investor Relations | ||
| John Paulson, Independent Director | ||
| Steven Miller, Independent Director | ||
| Thomas Appio, Executive Vice President Company Group Chairman, International | ||
| Robert Spurr, President - Salix | ||
| Cees Heiman, Senior Canada | ||
| Russel Robertson, Independent Director |
Bausch Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bausch Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.87 | ||||
| Return On Asset | 0.0382 | ||||
| Profit Margin | (0.07) % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 25.77 B | ||||
| Shares Outstanding | 366.67 M | ||||
| Shares Owned By Insiders | 0.91 % | ||||
| Shares Owned By Institutions | 79.41 % | ||||
| Number Of Shares Shorted | 20.71 M | ||||
| Price To Earning | 9.26 X |
Pair Trading with Bausch Health
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bausch Health position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bausch Health will appreciate offsetting losses from the drop in the long position's value.Moving together with Bausch Stock
| 0.72 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Bausch Health could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bausch Health when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bausch Health - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bausch Health Companies to buy it.
The correlation of Bausch Health is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bausch Health moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bausch Health Companies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bausch Health can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bausch Health Companies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Bausch Health Companies information on this page should be used as a complementary analysis to other Bausch Health's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Bausch Stock analysis
When running Bausch Health's price analysis, check to measure Bausch Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bausch Health is operating at the current time. Most of Bausch Health's value examination focuses on studying past and present price action to predict the probability of Bausch Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bausch Health's price. Additionally, you may evaluate how the addition of Bausch Health to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is Bausch Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bausch Health. If investors know Bausch will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bausch Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.115 | Earnings Share (1.62) | Revenue Per Share 23.998 | Quarterly Revenue Growth 0.098 | Return On Assets 0.0382 |
The market value of Bausch Health Companies is measured differently than its book value, which is the value of Bausch that is recorded on the company's balance sheet. Investors also form their own opinion of Bausch Health's value that differs from its market value or its book value, called intrinsic value, which is Bausch Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bausch Health's market value can be influenced by many factors that don't directly affect Bausch Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bausch Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bausch Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bausch Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.